Latest Clene Inc. News & Updates

See the latest news and media coverage for Clene. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Clene Inc. (Clene)

Clinical-stage biopharmaceutical company developing nanotherapeutics for neurodegenerative diseases

clene.com
Headquarters
SALT LAKE CITY, United States
Founded year
2013
Company type
Public company
Number of employees
70–200

Last updated

Latest news about Clene Inc. (Clene)

In short: Clene planned to submit an accelerated approval NDA for its ALS treatment CNM-Au8 in Q3 2026 following a successful Type C meeting with the FDA.

Company announcements

Clene

Clene announces $7 million stock offering

Offers 1,000,000 shares at $7.00 each to one investor. Proceeds fund NDA filing for CNM-Au8, expanded access, manufacturing, and R&D. Closes May 6, 2026.

Clene

Clene reports full year 2025 financial results

Announces FDA Type C meeting, oversubscribed $28M offering, and CNM-Au8 ALS progress. Cash runway extends to Q3 2026.

Unlock all announcements with a

Media coverage

The Globe and Mail

After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing...

Unlock all articles with a

Never miss news about Clene

Track Clene and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Clene competitors & trending companies

Browse news for competitors to Clene and other trending companies.